Latest KFF Health News Stories
Drug Coverage Denied By Medicare? How Seniors Can Fight Back
Senior citizens have to be patient and keep close records to appeal when Medicare plans refuse to cover their medicines.
En riesgo programas de salud en “ciudades santuario”
La dura posición del gobierno de Trump sobre inmigración podría estimular recortes en la financiación federal y complicar una amplia variedad de programas de salud en estas ciudades.
Trump’s Vow To Squeeze ‘Sanctuary Cities’ Could Play Havoc With Health Programs
Local health officials are bracing for the potential impact of a Trump administration policy that would stop federal funding to jurisdictions that don’t enforce federal immigration laws.
Negotiating Drug Prices: Should State Agencies Band Together?
A California lawmaker wants to strengthen collaboration among public agencies to bring down costs to taxpayers.
Widespread Hype Gives False Hope To Many Cancer Patients
Doctors and drug developers have a stake in making cancer treatments seem better than they really are.
A Spoonful Of Kids’ Medicine Makes The Profits Go Up
Even as drug pricing issues continue to draw scrutiny, federal safety regulations and incentives offer drug companies a new avenue to get a sweet return on their development costs.
Drugmakers Dramatically Boosted Lobbying Spending In Trump’s First Quarter
With high drug prices creating widespread controversy, top pharmaceutical companies and their trade group vastly increased their lobbying spending on Capitol Hill.
Marathon Pharmaceutical Drops Out Of PhRMA Following Drug Price Controversy
Two companies that faced criticism for high-priced drugs, Marathon and Mallinckrodt, have dropped out of the PhRMA trade association.
With Drug Costs In Crosshairs, Health Firms Gave Generously To Trump’s Inauguration
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
Readers: Training Patients To Advocate For Their Illnesses Is ‘A Virtue Not A Sin’
Kaiser Health News gives readers a chance to respond, react and comment on our stories.
Nonprofit Linked To PhRMA Rolls Out Campaign To Block Drug Imports
The advocacy group behind an expensive media blitz opposing Canadian drug imports has deep ties to the drug industry’s largest trade group.
Kids With Hepatitis C Get New Drugs And Coverage May Prove Easier Than For Adults
The drugs, approved by the FDA for children earlier this month, can run $100,000 for a course of treatment.
Drugmakers Help Turn Patients With Rare Diseases Into D.C. Lobbyists
Amplifying the “patient voice,” those with the rarest afflictions are trained to become powerful advocates for new drugs and legislation that would help the industry.
Another Circle Of Hell: Surviving Opioids In The Fentanyl Era
Unlike heroin, fentanyl routinely shuts down breathing in seconds, and it’s becoming more common.
VPH: nueva versión de la vacuna previene el contagio con solo dos dosis
Defensores de la salud pública esperan que con la nueva recomendación de administrar solo dos dosis de la vacuna contra el VPH a niñas y niños de entre 9 y 14 años las tasas de vacunación mejoren.
New Vaccine Recommendation Cuts Number Of HPV Shots Children Need
The vaccine protects kids against infection and several types of cancer but many parents have been reluctant to use it for their children.
Trump’s Promise To Rein In Drug Prices Could Open Floodgate To Importation Laws
Sen. Bernie Sanders’ bill to allow Americans to buy cheaper medicines from Canada would bypass a requirement that blocked past legislative efforts over two decades.
GAO To Launch Investigation Of FDA’s Orphan Drug Program
The Government Accountability Office said it will investigate potential abuses of the orphan drug program, which offers incentives to drugmakers to develop medicines for rare diseases.
Prescription Drug Costs Are On The Rise; So Are The TV Ads Promoting Them
Spending on consumer advertising by drugmakers has increased 62 percent since 2012.
Nueva droga baja el colesterol en forma drámatica y previene ataques, pero es costosísima
Por primera vez, una investigación muestra que un nuevo, y costoso, medicamento llamado Repatha no sólo baja dramáticamente los niveles de colesterol malo (LDL) sino que también reduce el riesgo de ser hospitalizado y de morir.
